Results 31 to 40 of about 39,473 (264)
Evidence of
Journal of Biomedical Science, 2010 Background l-Dopa has been used for Parkinson's disease management for a long time. However, its wide variety in the rate and the extent of absorption remained challenge in designing suitable therapeutic regime.
Wang Chun-Li +5 more
doaj +1 more source
Neurobiology of Disease, 2010 Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles +3 more
doaj +1 more source
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. [PDF]
PLoS ONE, 2008 L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study
Birger Scholz +11 more
doaj +1 more source
Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson’s disease
Frontiers in Systems Neuroscience, 2010 Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized by dopamine depletion in the striatum. One consistent pathophysiological hallmark of PD is an increase in spontaneous oscillatory activity in the basal ganglia ...
Youngbin Kwak +9 more
doaj +1 more source
Molecules, 2021 3,4-dihydroxyphenyl-L-alanine (L-DOPA) is a preferred drug for Parkinson’s disease, with an increasing demand worldwide that mainly relies on costly and environmentally problematic chemical synthesis.
Jiping Zhao +4 more
doaj +1 more source
Journal of Parkinson’s Disease, 2017 Today we would find it difficult to place ourselves in the position of the physician or the patient prior to the L-DOPA era of Parkinson’s Disease (PD). David Marsden, the eminent British neurologist, neuroscientist and PD researcher of the second half of the last century and an eyewitness to that historical turning point, paints with few brush strokes,
openaire +3 more sources
CSF Monoamine Metabolites and Cognitive Trajectory in Early Parkinson's Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background Imaging and postmortem studies indicate that abnormalities in monoaminergic neurotransmission contribute to cognitive impairment in Parkinson's disease (PD). However, it remains uncertain if cerebrospinal fluid (CSF) monoamine metabolites can serve as biomarkers of cognitive decline in early PD.
Jing‐Yu Shao +7 more
wiley +1 more source
Advanced Functional Materials, EarlyView.We propose a suture‐complementary approach that integrates optical skin clearing with a strain‐programmable luminescent adhesive patch. Hyaluronic acid promotes transdermal delivery of tartrazine to improve optical clearing and stabilizes its interaction with a photosensitizer. Optical clearing increases the penetration depth of visible light into skin,
Seong‐Jong Kim +6 more
wiley +1 more source
l-3,4-Dihydroxyphenylalanine induces ptosis through a GPR143-independent mechanism in mice
Journal of Pharmacological Sciences, 2016 Through its conversion to dopamine by aromatic l-amino acid decarboxylase (AADC), l-3,4-dihydroxyphenylalanine (l-DOPA) replenishes depleted brain dopamine in Parkinson's disease patients. We recently identified GPR143 as a candidate receptor for l-DOPA.
Suguru Ueda +3 more
doaj +1 more source
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. [PDF]
PLoS ONE, 2010 BackgroundRadiotracer imaging of the presynaptic nigrostriatal dopaminergic system is used to assess disease progression in Parkinson's disease (PD) and may provide a useful adjunct to clinical assessment during therapeutic trials of potential ...
Pierre-Olivier Fernagut +8 more
doaj +1 more source